# Omthera Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omthera-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Bedminster, US
- Website: www.omthera.com
- Total disclosed funding: $46M
- Latest round: Series B (Dec 31, 2011)
- Investors on record: 2

## About

Omthera Pharmaceuticals is focused on developing innovative biopharmaceutical products aimed at addressing critical health issues related to metabolic diseases and cardiovascular conditions, enhancing patient care through effective therapies.Founded in 2008, Omthera Pharmaceuticals is headquartered in Bedminster, US, and specializes in developing treatments for metabolic disorders. In 2013, the company underwent a Trade Sale, raising USD 443.00 mn in total funding, with AstraZeneca as the primary investor. It previously completed 6 deals, with the latest occurring on April 10, 2013, prior to its acquisition by AstraZeneca for USD 323 mn, which included an additional potential USD 120 mn based on drug performance.Omthera Pharmaceuticals develops and commercializes biopharmaceuticals targeting metabolic diseases. The company focuses on innovative therapies that address significant healthcare challenges, offering products that aim to improve the health outcomes of patients with specific metabolic disorders. Their research is centered around creating effective treatment options that meet the needs of healthcare providers and patients in various markets.In the most recent fiscal year, Omthera Pharmaceuticals reported an EBITDA of USD -27.53 mn, indicating the financial performance of the company in its operational context.Omthera Pharmaceuticals plans to leverage funding from its recent Trade Sale to enhance its product pipeline, focusing on the development of new therapies for metabolic diseases. The company aims to expand into key markets, specifically targeting regions in North America and Europe by 2025. The funding will also be utilized to support ongoing clinical trials and product launches, ensuring a robust entry into the competitive biopharmaceutical landscape.

## Funding rounds

- Series B, Dec 31, 2011, $5.1M — New Enterprise Associates, Sofinnova Partners
- Series B, Mar 14, 2011, $34M — New Enterprise Associates, Sofinnova Partners
- Series A, Nov 9, 2009, $6.5M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B